Identification of a Variable Number of Tandem Repeats Polymorphism and Characterization of LEF-1 Response Elements in the Promoter of the IDO1 Gene by Soichot, Marion et al.
Identification of a Variable Number of Tandem Repeats
Polymorphism and Characterization of LEF-1 Response
Elements in the Promoter of the IDO1 Gene
Marion Soichot
1, Benjamin Hennart
1, Alaa Al Saabi
1, Audrey Leloire
2, Philippe Froguel
2,3, Claire Levy-
Marchal
4, Odile Poulain-Godefroy
2, Delphine Allorge
1*
1Equipe d’Accueil 4483, Faculte ´ de Me ´decine de Lille, UDSL, Universite ´ Lille-Nord de France, Lille, France, 2CNRS 8199 - Institute of Biology, Pasteur Institute, Lille 2
University, Lille, France, 3Genomic Medicine, Imperial College London, Hammersmith Hospital, London, England, 4Institut National de la Sante ´ et de la Recherche
Me ´dicale, CIC EC 05, Ho ˆpital Robert Debre ´, Paris, France
Abstract
Background: Indoleamine 2,3-dioxygenase (IDO) catalyzes the first and rate-limiting step of the kynurenine pathway that is
an important component of immunomodulatory and neuromodulatory processes. The IDO1 gene is highly inducible by IFN-
c and TNF-a through interaction with cis-acting regulatory elements of the promoter region. Accordingly, functional
polymorphisms in the IDO1 promoter could partly explain the interindividual variability in IDO expression that has been
previously documented.
Methodology/Principal Findings: A PCR-sequencing strategy, applied to DNA samples from healthy Caucasians, allowed us
to identify a VNTR polymorphism in the IDO1 promoter, which correlates significantly with serum tryptophan concentration,
controlled partially by IDO activity, in female subjects, but not in males. Although this VNTR does not appear to affect basal
or cytokine-induced promoter activity in gene reporter assays, it contains novel cis-acting elements. Three putative LEF-1
binding sites, one being located within the VNTR repeat motif, were predicted in silico and confirmed by chromatin
immunoprecipitation. Overexpression of LEF-1 in luciferase assays confirmed an interaction between LEF-1 and the
predicted transcription factor binding sites, and modification of the LEF-1 core sequence within the VNTR repeat motif, by
site-directed mutagenesis, resulted in an increase in promoter activity.
Conclusions/Significance: The identification of a VNTR in the IDO1 promoter revealed a cis-acting element interacting with
the most downstream factor of the Wnt signaling pathway, suggesting novel mechanisms of regulation of IDO1 expression.
These data offer new insights, and suggest further studies, into the role of IDO in various pathological conditions,
particularly in cancer where IDO and the Wnt pathway are strongly dysregulated.
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Introduction
The heme enzyme indoleamine 2,3-dioxygenase (IDO ; EC
1.13.11.52) catalyzes the initial and rate-limiting step of the
kynurenine pathway that converts 95% of the essential amino acid
tryptophan (Trp) to kynurenine derivatives. IDO is constitutively
expressed in many cells and tissues and is also a cytokine-inducible
enzyme, with IFN-gamma (IFN-c) being the most potent known
transcriptional inducer of IDO. The overexpression of IDO has a
dual consequence: depleting Trp in local microenvironments and
increasing the concentration of downstream metabolites of the
kynurenine pathway.
IDO activation is of great interest in the field of immunology as
a consequence of Trp starvation, as well as the generation of
immunomodulatory kynurenine metabolites. It results in the
inhibition of growth of various pathogens and, thus, participates
in antimicrobial host defence mechanisms [1]. It has also a major
immunosuppressive role by suppressing local T-cell responses
[2,3], thus preventing, for example, allogeneic fetal rejection
during pregnancy [4,5]. This immune suppression via IDO
overexpression has also been shown to be involved in the immune
escape of tumor cells which is a crucial feature of cancer
progression [6]. As most of human tumors constitutively express
IDO, this enzyme could be considered as a predictive marker in
cancer progression and pharmacological IDO inhibition is
currently regarded as a future strategy in cancer adjuvant
immunotherapy [7–9].
Furthermore, as Trp is also involved in neurological functions as
a precursor in the synthesis of serotonin, a neurotransmitter that
modulates mood, cognition and several neuroendocrine rhythms
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25470[10], the kynurenine pathway appears to compete with the
serotoninergic pathway for Trp availability. An increase in IDO
activity consequently imbalances the kynurenine/serotonin path-
ways, thus resulting in a decrease of serotonin synthesis and an
accumulation of kynurenine metabolites, most of them displaying
neuroactive properties [11]. Accordingly, changes in peripheral
and/or central serotonin and kynurenine metabolites concentra-
tions have been shown to be involved in several neurodegenerative
disorders, such as Alzheimer’s and Parkinson’s diseases, as well as
in mental illnesses, such as schizophrenia and depression [11–13].
Additionally, IFN-alpha-induced activation of IDO is regarded as
being responsible for neuropsychiatric side effects, such as anxiety
and major depression, which can develop in patients chronically-
treated by IFN-a immunotherapy, and trigger non-compliance or
premature discontinuation of treatment [14,15].
Although the role of IDO and its induction by cytokines are
now well recognized, not many studies have focused on the
mechanisms of variability of IDO activity, which could have
numerous relevant clinical implications. In vitro studies have shown
that the response of IDO to IFN-c stimulation varies greatly
between various human cell lines [16,17]. Based on the
kynurenine/tryptophan ratio, which is calculated from circulating
concentrations and is recognized as a valid indicator of IDO
activity [18], it appears that IDO activity exhibits relatively large
interindividual variability, in particular in pathological conditions
[19–24]. Indirect evidence of interindividual variability in IDO
activity, and/or inductibility, is also supported by several studies
that showed that the development of IFN-a-induced neuropsychi-
atric symptoms only occurs in 20–50% of cancer- or hepatitis C-
treated patients [15,25,26].
The currently known causes of variation in IDO activity remain
sparse. Physiological states such as ageing or pregnancy, as well as
pathological conditions such as infection, inflammation or tumor
proliferation, have been demonstrated to modify IDO expression
and/or activity, but they all mainly reflect the various mechanisms
involved in the regulation of IDO expression [13,27]. However, it
can be postulated that genetic factors could be involved in
interindividual variability of IDO expression and/or activity. An
indirect genetically-controlled mechanism of variation of expres-
sion is illustrated by a c.874T.A polymorphism that affects a NF-
kB response element in the IFN-c gene and, consequently, IFN-c
production, which in turn alters IDO up-regulation [28,29]. Only
one study, to our knowledge, has reported two rare naturally-
occurring polymorphisms in the IDO-encoding gene (IDO1) which
were shown in vitro to be responsible for impaired functional
activity and could therefore result in reduced IDO activity in the
general population [30]. However, in this study, only the 10 exons
and the exon/intron junctions of IDO1 were screened for
nucleotide variations. As the promoter of IDO1 carries numerous
well-identified responsive element sequences that are involved in
the regulation of IDO expression [17,31–34], it prompted us to
search for genetic polymorphisms in this functionally-crucial
region of the IDO1 gene. The screening of the IDO1 promoter
in healthy Caucasian subjects allowed us to identify a Variable
Number of Tandem Repeats (VNTR) polymorphism. A signifi-
cant association of this VNTR with decreased circulating
tryptophan concentrations was observed in healthy female
subjects. The contribution of the VNTR polymorphism to the
variability of IDO expression was further studied by functional
analyses. Using in vitro and in silico approaches, we revealed the
existence of previously unknown cis-acting regulatory elements
that could participate in transcriptional regulation and, therefore,
in interindividual variability of IDO1 expression.
Results
Identification of a functional VNTR polymorphism on the
IDO1 promoter
To investigate potential sequence variations in the promoter
region of IDO1, a PCR-sequencing strategy was developed and
applied to a 1576 bp-sequence upstream of the ATG initiation
codon. Sequencing was applied to PCR products amplified from
genomic DNA samples of 41 unrelated healthy individuals of
Caucasian origin. A VNTR polymorphism was identified in both
heterozygous and homozygous states. This VNTR polymorphism
comprises a 24-bp tandem repeat motif located approximately 1.3
kb upstream of the ATG initiation codon (Figure 1). This
polymorphism is referenced as a deletion/insertion polymorphism
with the RefSNP rs34820341 in NCBI. Here, we termed the two
alleles containing one or two repeats,*V1 and *V2, respectively. The
*V1allelecorrespondstothereferencesequenceofIDO1availablein
the GenBank database with the accession number NT_007995 and
the sequence of the *V2 allele has been deposited in GenBank under
the accession number JN382541. No other mutation was identified
in the 1.6-kb promoter region of the 41 sequenced DNA samples.
The genotype and allele frequencies of the VNTR polymorphism
in the 41 Caucasian volunteers, that were calculated based on the
sequencing approach, are shown in Table 2. Using a rapid PCR-
based genotyping assay, statistically similar genotype and allele
frequencies were observed with the 300 DNA samples from the
Haguenau cohort (Table2).The frequency of the *V1 and *V2 alleles
is around 46–48% and 52–54%, respectively, and the distribution of
the VNTR genotypes respects the Hardy-Weinberg law.
In order to study the possible association between the VNTR
genotype and IDO activity, tryptophan and kynurenine concen-
trations were measured in sera from 94 subjects of the Haguenau
cohort, comprising 47 males (16 *V1/*V1,1 6*V1/*V2 and 15
*V2/*V2) and 47 females (15 *V1/*V1,1 5*V1/*V2 and 17 *V2/
*V2). As serum samples were collected after an overnight fast, the
effects of diet on circulating Trp levels can be considered as
negligible. First, the complete sequencing of the 1.6-kb promoter
region of IDO1 excluded the presence of any other polymorphism
in the 94 tested samples, and none of the samples carried the
functional coding variants, i.e. the 9-bp deletion and/or the
rs35099072 SNP. Mean (6 S.D.) values of serum Trp (mM), serum
Kyn (mM) and Kyn/Trp ratio (mmol/mmol), in all tested subjects,
as well as in males and females separately, are reported according
to VNTR genotypes in Table 3. Mean values (6 S.D.) of each
parameter are also shown independently of the VNTR genotypes.
It could be observed that only the mean serum Trp concentration
was significantly lower in females compared to males
(54.9613.6 mM versus 66.1615.6 mM; p=0.0006). In all subjects,
no statistically significant association was observed between the
VNTR genotype and serum Trp, serum Kyn or Kyn/Trp ratio.
However, a lower Trp concentration was observed for females
with a *V2/*V2 genotype compared to those with a *V1/*V1
(p=0.076) or a *V1/*V2 (p=0.028) genotype. Furthermore, the
Trp concentration in females with a *V2/*V2 genotype was
significantly lower than that in males with a *V1/*V1 (p=0.008),
*V1/*V2 (p=0.01) and *V2/*V2 (p=0.0007) genotype.
Effect of the VNTR polymorphism on the promoter
activity of IDO1
A gene reporter assay was developed in order to assess the
impact of the VNTR on the transcriptional activity of the IDO1
promoter. The luciferase activities shown in Figure 2A (see also
Table S1) were measured under basal conditions or after
stimulation by IFN-c and/or TNF-a. Under basal conditions,
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increased 2.5-fold compared to the insertless promoter, which
confirms that the 1.6-kb promoter region of IDO1 has significant
transcriptional activity. The transcriptional activity of the IDO1
promoter was also evaluated after 24 h stimulation with IFN-c
and/or TNF-a, two cytokines that are known to induce IDO1
expression. Stimulation by IFN-c and TNF-a separately showed a
respective 105- and 10-fold increase in luciferase activity of the
Figure 1. Cis-acting regulatory elements of the 1.6-kb promoter region of IDO1. Nucleotides ranging from -1567 upstream to 9 downstream
of the translation initiation site (ATG) are shown. Transcription factor binding sites previously described (ISRE and GAS sites) or predicted by
MatInspector (LEF-1/TCF sites) are underlined and named below the sequence. The VNTR motif is in bold letters.
doi:10.1371/journal.pone.0025470.g001
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(p,0.001). Stimulation in the presence of both IFN-c and TNF-a
resulted in a 250- and 277-fold increase in *V1 and *V2 luciferase
activity, respectively (p,0.001 for both alleles). These data
confirm the induction of IDO1 expression via a transcriptional
mechanism through cytokines stimulation. Note, however, no
statistical difference was observed between *V1 and *V2 luciferase
activities in any of the above experimental conditions.
Effect of the VNTR polymorphism on potential DNA-
protein interactions
To assess whether the VNTR polymorphism could have an
influence on upstream regulatory factors of the IDO1 promoter,
the 1.6-kb promoter region of IDO1 was analysed using
MatInspector prediction software. Three critical putative binding
sites for the LEF-1/TCF transcription factor were identified in the
*V1 allele, one site being located within the 24-bp motif of the
VNTR, as shown in Figure 1. Consequently, the *V2 allele, which
carries two repeat motifs of the VNTR, exhibits four potential
TFBSs for LEF-1/TCF in the 1.6-kb promoter region.
ChIP assays were used to confirm the presence of potential
binding sites for LEF-1/TCF predicted by MatInspector. The
assays were conducted with extracts of HeLa cells, that were
genotyped as homozygotes for the *V1 allele, and the successful
chromatin immunoprecipitation was checked via the GAPDH
positive control. Three specific primer pairs were designed for PCR
amplification of LEF-1 genomic sequences from immunoprecipita-
tes.The results shown in Figure 3 indicate that LEF-1 binds to the
three potential sequences in the IDO1 promoter, which confirms the
LEF-1/TCF binding sites predicted by MatInspector.
To evaluate the functional significance of the additional TFBS
for LEF-1/TCF in the *V2 allele relative to *V1, gene reporter
assays were conducted with the overexpression of an activated
form of LEF-1. In this assay, activated LEF-1 is expressed due to
the VP16-TCF expression vector possessing a virtual DNA-
Table 1. Primers used for IDO1 promoter sequencing, VNTR genotyping, site-directed mutagenesis and post-ChIP PCR.
Primer designation Primer sequence (59R39)
a
Primers for amplification and cloning
b of the IDO1 promoter (-1567 to -16)
IDOCLON-F AAGatATCCGCCCTCCTCAGCTTC (-1567 to -1544)
IDOCLON-R GTGTGCCATggTTGTAGTCTGCTCC (-16 to +9)
Primers for sequencing of the IDO1 promoter
IDOPR-Seq1F ATTCCCAAAGTATTAGCCTC (-1235 to -1216)
IDOPR-Seq2F CAATGCCTCTAAAGTGAACC (-868 to -849)
IDOPR-Seq1R CCATATAGGAAGCCAGAAAGGCC (-271 to -293)
IDOPR-Seq2R GGTTACTTTAGAGGCATTG (-849 to -868)
Primers for VNTR genotyping (-1421 to -1232)
IDOPR-F AATCCTGGGACAGAATCATC (-1421 to -1402)
IDOPR-R ATGAGGCTAATACTTTGGG (-1214 to -1232)
Primers for site-directed mutagenesis
c
IDOMUT-F CCCATAAAAACTTCAAGTACGACGAATGAAAAATAACCAC (-1368 to -1329)
IDOMUT-R GTGGTTATTTTTCATTCGTCGTACTTGAAGTTTTTATGGG (-1329 to -1368)
Primers for amplification of immunoprecipitated target sequences
GAPDHPR-F TACTAGCGGTTTTACGGGCG
GAPDHPR-R TCGAACAGGAGGAGCAGAGAGCGA
IDOPR-site1-F AATCCTGGGACAGAATCATC (-1421 to -1402)
IDOPR-site1-R ATGAGGCTAATACTTTGGG (-1214 to -1232)
IDOPR-site2-F CCTACTTCAGAGCCATTGAC (-530 to -511)
IDOPR-site2-R GCAGTCCTAAACTCTCATTT (-386 to -405)
IDOPR-site3-F AAATGAGAGTTTAGGACTGC (-405 to -386)
IDOPR-site3-R CTTACTGCCATATAGGAAGC (-264 to -283)
F: forward; R: reverse
aPositions of the primers are based on the translational start site, with +1 corresponding to the adenine of the ATG codon.
bEcoRV and NcoI recognition site sequences (underlined nucleotides) were created in the primers for the cloning step of the IDO1 promoter region.
cBold letters represent the mutated nucleotides for site-directed mutagenesis.
doi:10.1371/journal.pone.0025470.t001
Table 2. Genotypic and allelic frequencies of the VNTR
polymorphism in the IDO1 promoter.
Number of individuals Number of individuals
Genotype N=41
a n=300
b Allele n=41
a n=300
b
*V1/*V1 22% 23.8% *V1 46% 48.1%
*V1/*V2 49% 48.6% *V2 54% 51.9%
*V2/*V2 29% 27.6%
aThe genotype and allele frequencies for the 41 DNA samples obtained from
unrelated healthy Caucasian volunteers were calculated based on a
sequencing approach, as described in the Material and Methods section.
bThe genotype and allele frequencies for the 300 DNA samples obtained from
the Haguenau cohort were calculated based on a PCR-based genotyping
strategy, as described in the Material and Methods section.
doi:10.1371/journal.pone.0025470.t002
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place of a b-catenin-binding domain [35]. For each situation, a
negative control was conducted comprising an empty expression
vector (pcDNA3.3). As previously, the promoter activity of both
alleles was assessed in the presence and absence of cytokinic
stimulation, and compared to the promoterless pGL4 vector
(Figure 2B). With or without cytokinic stimulation, the luciferase
activities of pGL4-V1 and pGL4-V2 were significantly enhanced
in the presence of LEF-1 compared to co-transfection with the
negative control (data not shown). Furthermore, the induction
effect of IFN-c and TNF-a and the synergistic effect of their
association were also observed, as previously noted (Figure 2A/B).
This second set of transfections showed that the presence of Wnt-
activated LEF-1 increased the IDO1 promoter activity for both
*V1 and *V2 alleles. However, under the experimental conditions,
no significant difference in promoter activity was observed
between the two VNTR alleles.
Effect of the LEF-1/TCF site located in the VNTR on IDO1
promoter activity
To investigate the influence of the TFBS for LEF-1/TCF on the
transcriptional activity of the 1.6-kb promoter region of IDO1, the
*V1 allele was modified by mutating the core sequence of the
binding site localized in the 24-bp motif of the VNTR by site-
Figure 2. Functional analyses of *V1, *V2 and *V1Mut alleles of the IDO1 promoter in HeLa cells. The four promoter constructs (pGL4-V1,
pGL4-V2, pGL4-V1Mut and the promoterless pGL4-basic vector) and a renilla control vector (pGL4.74), without (A) or with (B) the VP16-TCF expression
vector, were transiently transfected into HeLa cells. The luciferase activities were measured in basal conditions, or after stimulation by IFN-c (10 ng/
mL), TNF-a (5 ng /mL), or combined IFN-c and TNF-a (10 ng/mL and 5 ng/mL, respectively). Results, expressed as relative firefly luciferase units
normalized to renilla luciferase, are the mean 6 SEM of triplicates from three independent experiments and are presented on a linear scale. Asterisks
indicate statistical significance of * p,0.05 and ** p,0.001.
doi:10.1371/journal.pone.0025470.g002
Table 3. Mean serum concentrations (6 S.D.) of tryptophan (Trp), kynurenine (Kyn) and Kyn/Trp ratio in 94 healthy Caucasian
subjects according to their IDO1 VNTR genotype.
All subjects Males Females
(n=94) (n=47) (n=47)
*V1/*V1 *V1/*V2 *V2/*V2 *V1/*V1 *V1/*V2 *V2/*V2 *V1/*V1 *V1/*V2 *V2/*V2
(31) (31) (32) (16) (16) (15) (15) (15) (17)
Trp 60.5615.6 66.1615.5 55.0613.6
a
(mM) 62.3616.1 59.1611.2 60.2618.7 66.4617.3 60.4611.8 71.8615.9 57.9614.0 57.7610.6
b 50.0614.9
c,d
Kyn 2.160.9 2.260.9 2.160.9
(mM) 2.161.1 2.260.8 2.160.9 2.161.1 2.260.8 2.460.8 2.261.0 2.360.9 1.860.9
Kyn/Trp 35.4613.5 33.4611.1 37.4615.4
(mmol/mmol) 34.5617.5 37.6611.4 34.2610.7 30.6613.3 35.6610.6 34.068.9 38.7620.9 39.7612.3 34.4612.3
ap,0.001 when comparing females and males.
bp,0.05 when comparing females *V1/*V2 and males *V2/*V2.
cp,0.05 when comparing females *V2/*V2 and females *V1/*V2.
dp,0.01 when comparing females *V2/*V2 and each subgroup of males, *V1/*V1, *V1/*V2 and *V2/*V2.
doi:10.1371/journal.pone.0025470.t003
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no longer identify a binding site at this location. Thus, a third
pGL4 construct containing the mutated core sequence of the LEF-
1/TCF binding site (pGL4-V1Mut) was used in gene reporter
assays, as described previously (Figure 2). As shown in Figure 2A,
in basal conditions, the relative luciferase activity of pGL4-V1Mut
was significantly increased compared to the control pGL4 vector,
as well as compared to pGL4-V1 and pGL4-V2 constructs
(p,0.001). Induction by IFN-c or TNF-a increased the relative
luciferase activity of pGL4-V1Mut 108- and 12-fold, respectively,
with a synergistic effect of the combined cytokines resulting in a
292-fold increase, compared to that in basal conditions. However,
the luciferase activities following IFN-c or TNF-a stimulation were
not statistically different between *V1, *V2 and *V1Mut alleles.
Interestingly, the synergistic effect of the two cytokines resulted in
a significantly higher relative luciferase activity for pGL4-V1Mut
compared to that of pGL4-V1 (p,0.05).
Additional gene reporter assays conducted with the overexpres-
sion of an activated form of LEF-1 showed no statistical difference
in the promoter activity of pGL4-V1Mut compared to pGL4-V1
and pGL4-V2, under basal conditions (Figure 2B). Furthermore,
as in the absence of VP16-TCF, no significant differences were
observed between the three constructs following a single
stimulation with IFN-c or TNF-a. However, the relative luciferase
activity of pGL4-V1Mut was significantly higher following a
combined cytokinic stimulation, with a 1.3-fold increase compared
to pGL4-V1 and pGL4-V2 (p,0.05).
Discussion
Variability in IDO activity can result in significant imbalances
in the serotonin/kynurenine pathways which could have clinical
immunological and neuropsychiatric implications. As inherited
variants of coding and non-coding sequences of a gene are
recognized as an important cause of interindividual variations in
protein expression and/or activity, the identification of functional
genetic polymorphisms in the IDO1 gene would be of particular
interest in association studies between IDO and various patho-
logical conditions. Several variations in the IDO1 genomic
sequence have already been documented in sequence databases,
but their functional consequences have not yet been studied [36].
In a recent study, Arefayene et al. [30] sequenced DNA samples of
African-American and Caucasian origin and identified seventeen
different polymorphisms in the 10 exons and intron-exon junctions
of the IDO1 gene. Two of these, a missense mutation (p.Arg77His;
rs35099072) and a 9-bp deletion in exon 7, result, in vitro, in
significantly reduced protein expression and, consequently, in
almost complete loss of enzyme activity [36]. However, these
functional variants appear to be very rare IDO1 polymorphisms,
since each was identified in only one African-American subject,
and, accordingly, can be expected to have a minor phenotypic
effect in the general population. In addition, Nishizawa et al. [37]
studied IDO1 genomic variations as a potential determinant of pre-
eclampsia. The sequencing of placental genomic DNA from pre-
eclamptic and normotensive pregnant women revealed three new
rare IDO1 variants, consisting of one silent mutation, one missense
mutation (p.Arg193Gly) and a 4-bp deletion in the proximal 59-
UTR. However, no functional analyses were performed for the
two coding SNPs, and the 4-bp deletion did not affect gene
expression of IDO1 in in vitro experiments [37].
As promoter regions control gene expression by interactions
between cis-acting elements spanning through the promoter region
and transcription factors, variations in the sequence of cis-acting
elements could have an effect on gene expression [38]. In the case
of IDO1, the promoter region has been well characterized and
contains several cis-acting response elements that are involved in
the up-regulation of the gene by cytokines, such as IFN-c, the most
potent inducer of IDO activity, as well as TNF-a [17,32,33]. Two
Interferon-Stimulated Response Elements (ISRE) and three
Gamma Activated Sequence (GAS) located within the 1300-bp
upstream of the ATG initiation codon appear to be critical for
maximal IDO1 promoter activity, with a synergistic activation by
IFN-c and TNF-a [17,32,33]. In the present study, we identified a
VNTR polymorphism in the IDO1 promoter region, consisting of
a 24-bp repeat motif located 1.3-kb upstream of the ATG
initiation codon. It was identified by a PCR-sequencing strategy
applied to 41 DNA samples and allowed us to characterize two
different alleles, named *V1 and *V2, that carry one or two
repeats, respectively, the *V1 allele corresponding to the reference
sequence listed in Genbank (accession number NC_000008.10).
This polymorphism appears to be common in Caucasians, the
frequency of the *V1 allele being 46–48% and that of the *V2
variant being 52–54% in our study. No additional VNTR allele
with more than two motif repeats was identified.
To assess the impact of the VNTR polymorphism on IDO
activity, 47 males and 47 females from a cohort of 300 healthy
Caucasian subjects were selected based on their genotype, and
Figure 3. Binding of LEF-1 to the 1.6-kb IDO1 promoter. PCR products were obtained from immunoprecipitates after ChIP assays of HeLa cells
and loaded on a ethidium bromide stained-1% agarose gel. Three specific oligonucleotide primer pairs were used to confirm the presence of the
three potential LEF-1/TCF binding sites on the 1.6 kb IDO1 promoter region, as predicted by MatInspector. The three corresponding amplicons are
sized 208 bp (site 1), 145 bp (site 2) and 142 bp (site 3). Positive controls (Input chromatin DNA before immunoprecipitation), negative controls
without antibody (Ab-) and immunoprecipitation with anti-LEF-1 antibody are indicated for each amplified fragment of the IDO1 promoter. Site 1
refers to the putative LEF-1 binding site within the 24-bp motif of the VNTR; sites 2 and 3 refer to the two additional LEF-1 sites predicted by
MatInspector.
doi:10.1371/journal.pone.0025470.g003
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tions. We first observed a significant lower serum Trp concentra-
tion in females compared to males, as reported previously in other
studies [39–41]. Furthermore, females with a *V2/*V2 genotype
displayed a significant and a trend toward lower serum Trp
concentration compared to females with a *V1/*V2 and *V1/*V1
genotype, respectively. IDO is known to be induced by soluble
hormones, such as human chorionic gonadotropin, prolactin and
estrogens, supporting the hypothesis of a hormonal control of IDO
expression [42–45]. It can then be postulated that the VNTR
polymorphism we identified has an effect on Trp metabolism
under the influence of a female hormonal environment, which is
partly supported by Carretti et al. [46] who showed that circulating
Trp concentration has cyclic variations throughout the menstrual
cycle.
In our experiments involving HeLa cells, a cell line which was
previously used to study the mechanism of IFN-c action on IDO1
promoter activity [16,32], luciferase reporter assays showed that
the 1.6-kb fragment upstream of the translation start site is a
functional promoter of IDO1, and that both IFN-c and TNF-a
induce promoter activity, a greater activation being obtained with
IFN-c and a synergy being observed with a combination of the two
cytokines. However, no significant difference in promoter activity
was seen between *V1 and *V2 alleles under any experimental
condition. Based on these results, the absence of any difference in
promoter activity between the two alleles, even after synergistic
induction, may not have been unexpected, since the VNTR
polymorphism does not modify any critical response element, such
as ISRE or GAS.
A bioinformatic analysis was undertaken to predict potential cis-
acting elements in the promoter region of IDO1 in order to
investigate whether the VNTR polymorphism could affect
interactions between putative binding sites and transcription
factors. In addition to the response elements for IFN-c and
TNF-a previously described, the in silico analysis predicted that the
LEF-1/TCF transcription factor could interact with the promoter
region of IDO1 at three different sites, with one putative consensus
sequence being located in the 24-bp motif of the VNTR. As TFBS
prediction programs cannot assert the existence of a TFBS or infer
the functionality of a site [47], additional experiments were
undertaken. Initially, the presence of the three potential binding
sites for LEF-1 in the IDO1 promoter was confirmed by specific
PCR amplifications using chromatin immunoprecipitation of
HeLa cellular extracts. To investigate the functionality of the
potential sites, additional gene reporter assays were performed
using an overexpression of a functional LEF-1. As a member of the
TCF/LEF family of transcription factors, LEF-1 is one of the
major nuclear transducers involved in Wnt signaling. However, it
has no transcriptional activation potential in isolation and requires
binding with b-catenin, the b-catenin activation domain and
TCF/LEF DNA-binding domain forming a bipartite transcrip-
tional activator of target genes [48]. VP16-TCF is a plasmid
construct that expresses a form of LEF-1 fused to the potent VP16
transactivation domain which is constitutively active and obviates
the need for a b-catenin TCF/LEF interaction [35,49]. In the
presence of VP16-TCF, the promoter activity of the *V1 and *V2
alleles was found to be significantly increased relative to the
negative control expression vector, thus confirming the existence
of specific and functional binding sites for LEF-1 on the studied
1.6-kb promoter region of IDO1. This result confirms the
reliability of MatInspector prediction of potential binding sites
for this transcription factor. However, no difference in promoter
activity was observed between *V1 and *V2 alleles, thus suggesting
the insertion of the 24-bp motif, that creates one additional copy of
a LEF-1 response element, may not interact with LEF-1, and,
furthermore, that the other three LEF-1 sites most likely contribute
to the global increase of IDO1 promoter activity following
overexpression of LEF-1. Interestingly, following IFN-c and/or
TNF-a stimulation, promoter activities of *V1 and *V2 alleles were
similarly increased, but to a lesser extent than those observed in
the first experiments without LEF-1 overexpression, relative to the
promoterless pGL4 vector. These results suggest the interaction
between LEF-1 response elements and VP16-TCF product alters
the IDO1 promoter responsiveness to cytokines. It is noteworthy
that Robinson et al. [33] showed previously that the deletion of a
large sequence between the two ISRE sites in the IDO1 promoter
gave rise to a significant increase of transcription activation by
IFN-c, compared to that observed with the undeleted promoter.
Accordingly, the authors suggested that regulatory elements within
this region could provide additional mechanisms of IDO1
regulation. As two of the LEF-1 sites we characterized are located
between the two ISRE sites, they could then be hypothesized to
correspond to those suggested additional cis-acting elements in the
IDO1 promoter.
The modification, by site-directed mutagenesis, of the LEF-1
binding site located within the 24-bp motif of the VNTR,
appeared to increase IDO1 promoter activity relative to the activity
of the *V1 and *V2 alleles, suggesting that the LEF-1 site within
the VNTR has a repressive effect on IDO1 promoter activity. This
result could be explained by the fact that LEF-1 can also interact
with proteins of the Groucho family, proteins that are known to
repress transcriptional activation by b-catenin-TCF complexes
[48,50–52]. However, the effect of the pGL4-V1mut construct on
luciferase activities appears rather marginal compared to that of
cytokine stimulation.
In conclusion, we have characterized a previously unknown
VNTR polymorphism in the promoter region of the IDO1 gene.
Although this VNTR appears to have no major consequence on
basal or cytokine-induced transcriptional activity in vitro, it seems
to participate in Trp homeostasis in female subjects. Furthermore,
the identification of this polymorphism has uncovered previously
unknown cis-acting elements for the LEF-1 transcription factor.
Variations in the number of these response elements could alter
IDO1 expression, particularly in pathological conditions involving
the Wnt signaling pathway.
Materials and Methods
Biological samples and ethics statement
41 anonymous DNA samples, previously obtained from
unrelated healthy Caucasian volunteers and declared to the
Commission Nationale de l9Informatique et des Liberte ´s for
research studies on genetic polymorphism identification (SPFCO/
cellule de bioe ´thique/nu DC-2008-642), were used to screen the
genomic sequence of the IDO1 promoter.
A further 300 serum and DNA samples from young healthy
adults, prepared as previously described by Bouatia-Naji et al. [53],
were selected from the Haguenau cohort whose study was
approved by the ethics committee of Paris-St Louis University,
Paris, France [54]. All experiments were approved by the IRB at
Paris-St Louis University, Paris, France (permit number: protocole
2006/05-C05-57). The Haguenau cohort had been fully described
previously [54]. Briefly, this cohort included subjects selected
between 1971 and 1985 from a population-based registry in the
city of Haguenau, France, who were initially classified in two sub-
groups based on birth data. At 22.163.9 years of age, participants
gave blood samples for serum and DNA analyses in order to study
predisposition to various metabolic disorders. From these serum
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from subjects who were born with appropriate gestational age and
presented no metabolic disorder at adult age. The serum samples
were collected after an overnight fast.
A written informed consent was obtained from all participants.
Sequencing of the IDO1 promoter region
The promoter region of the IDO1 gene from each of the initial
41 DNA samples was sequenced in order to screen for genetic
polymorphisms. Accordingly, a DNA fragment covering the 1576
bp-sequence upstream of the ATG initiation codon was amplified
from each DNA sample using Phusion
TM High-Fidelity DNA
polymerase (Ozyme, Saint-Quentin-en-Yvelines, France), accord-
ing to the manufacturer’s instructions. Each fragment was directly
sequenced using the BigDyeH Terminator v3.1 cycle sequencing
kit (Applied Biosystems, Courtaboeuf, France) and an automated
3130XL genetic analyzer (Applied Biosystems). All primers were
designed according to the nucleotide sequence of the IDO1 gene
published in GenBank (accession number NT_007995) and are
listed in Table 1.
Genotyping assay for VNTR identification
A rapid and simple genotyping assay was developed to genotype
the VNTR polymorphism that was identified within the IDO1
promoter region and applied to the 300 DNA samples from the
Haguenau cohort. A short PCR fragment encompassing the
VNTR region was amplified with a pair of specific primers
(Table 1). The PCR reaction was carried out in a final volume of
25 mL using Taq DNA polymerase (Invitrogen, Cergy Pontoise,
France) and the amplicons separated on 10% acrylamide gel and
visualized using UV transillumination after ethidium bromide-
staining. The discrimination between a 208-bp fragment (*V1
allele) and a 232-bp fragment (*V2 allele) allowed the character-
ization of the VNTR genotype of each sample.
Genotyping assays for two rare polymorphisms in the
coding sequence of IDO1
Additional IDO1 genotyping assays were performed on 94 out of
the 300 DNA samples from the Haguenau cohort to screen the 9-
bp deletion and the rs35099072 SNP, previously characterized as
functional IDO1 variants by Arefayene et al. [30]. The corre-
sponding PCR and sequencing conditions are available on request.
Bioinformatics analysis
The prediction software MatInspector (www.Genomatix.de)
was used to search the IDO1 gene for potential Transcription
Factor Binding Sites (TFBSs) in the 1.6-kb promoter region. A
restrictive threshold of 0.85 and the matrix library v7.0 were used.
Plasmid constructs and site-directed mutagenesis
Genomic DNA samples carrying a homozygous VNTR
genotype, i.e. *V1/*V1 or *V2/*V2, were used to amplify a
1576-bp or 1600-bp fragment, respectively, using a pair of primers
that were previously used to sequence the IDO1 promoter
(Table 1). These primers allow the amplification of a PCR
fragment with EcoRV and NcoI sites at the 59- and 39-ends,
respectively. Following amplification and purification, the frag-
ments were double-digested by EcoRV and NcoI endonucleases
(Gentaur, Paris, France) and subsequently cloned into the
pGL4.11 [Luc2P] vector (Promega, Charbonnie `res, France) which
contains the firefly luciferase cDNA. After cloning, both recombi-
nant vectors pGL4-V1 and pGL4-V2 were sequence-verified to
avoid constructs containing sequence mismatches and correct
orientation confirmed.
The LEF-1/TCF consensus sequence identified in the repeat
motif of the VNTR by MatInspector was mutated using the
QuickChange II Site Directed Mutagenesis Kit (Agilent Technol-
ogies, Massy, France), according to the manufacturer’s recom-
mendations. This mutagenesis step was applied to the pGL4-V1
construct with complementary primers designed to create a 2-bp
change in the LEF-1/TCF core sequence. The corresponding
plasmid was named pGL4-V1Mut and was used for gene reporter
assays. The sequences of the mutated primers are shown in
Table 1.
Transient transfection and luciferase assays
The HeLa human cervical carcinoma cell line (LGC Standards,
Molsheim, France) was maintained and cultured in DMEM
supplemented with 1% of a combined solution of 100 U/mL
penicillin and 100 mg/mL streptomycin and 10% FBS (Invitrogen).
T h ec e l l sw e r eg r o w ni n5 %C O 2 at 37uC. The day before
transfection, 4.10
4cells were freshly plated on 24-well plates in 0.5 mL
of complete media. Twenty-four hours after plating, HeLa cells were
transfected with 1.25 mL of lipofectamine LTX (Invitrogen).
In a first set of transfection experiments, HeLa cells were
transfected with 250 ng of the insertless pGL4.11-basic vector or
one of the recombinant vectors, pGL4-V1, pGL4-V2 and pGL4-
V1Mut, and 12.5 ng of the control reporter PGL4.74 plasmid
(Promega) that contains the renilla luciferase, used to normalize
transfection efficiency. Four hours after transfection, the medium
was removed and replaced with fresh complete medium with or
without IFN-c (10 ng/mL), TNF-a (5 ng/mL), or a combination
of both cytokines (Sigma-Aldrich, Saint Quentin-Fallavier,
France). Luciferase activities were measured 24 h after cytokine
induction.
In a second set of transfections, 125 ng of the pGL4.11 basic
vector or one of the promoter constructs was co-transfected with
12.5 ng of PGL4.74 and 125 ng of the expression vector VP16-
TCF; pcDNA 3.3 was used as a negative expression control. As
previously, a cytokine induction was performed 4 h after
transfection and luciferase activities were measured 24 h later.
The luciferase activities were measured using the Dual-Glo
Luciferase Reporter Assay System (Promega) following the
manufacturer’s recommendations. The firefly luciferase activity
(fLA) and the renilla luciferase activity (rLA) were measured
sequentially with a Glomax luminometer (Promega). The relative
luciferase activity (RLA) was calculated as follows: RLA = fLA/
rLA. The transfection and reporter gene assays were performed in
triplicates and repeated in three independent experiments. Results
are expressed as relative firefly luciferase units normalized to renilla
luciferase. Data are expressed as mean 6 SEM.
Chromatin Immunoprecipitation
ChIP analysis was performed according to the Upstate
Biotechnology (Millipore, Molsheim, France) protocol with
modifications. 3.10
6 HeLa cells were cross-linked for 10 min at
37uC in 1% formaldehyde. Cross-linking was stopped by adding
0.125 M of glycine for 5 min at room temperature. Cells were
then washed twice with cold PBS 1X, re-suspended in 300 mLo f
SDS lysis buffer containing protease inhibitors and pelleted for
5 min at 2000 g at 4uC. Cross-linked DNA was sheared by
sonication to yield DNA fragments between 200 and 500 bp in size
and then diluted 10-fold with ChIP dilution buffer. At this step,
20 mL of the sample was used as input material to quantify the
amount of DNA present in each sample before immunoprecip-
itation. Samples were pre-cleared for 4 h with 75 mL of protein A-
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ed overnight at 4uC with rotation with 10 mg of an antibody to
acetylated histone H3 (Millipore) for positive control experiments,
20 mg of an anti-LEF-1 antibody (Tebu Bio, Le Perray en
Yvelines, France), or without antibody as a negative control.. The
following day, 60 mL of protein A-agarose/salmon sperm DNA
(50% slurry) was added to the sample for 4 h at 4uC with agitation
to collect the antibody/histone complex. Beads were then
collected by gentle centrifugation and washed according to the
Upstate protocol. The histone complexes were eluted from the
beads with 500 mL elution buffer (1% SDS, 0.1 M NaHCO3) at
room temperature for 30 min with rotation. Cross-links were
reversed by adding 20 mL of NaCl 5M to the eluates and heating
at 65uC overnight. The sample was then treated with 10 mLo f
0.5 M EDTA, 20 mL of 1 M Tris-HCl, pH 6.5, and 2 mLo f
10 mg/mL Proteinase K for 2 h at 45uC. DNA was recovered by
phenol/chloroform extraction and ethanol precipitation. PCR
used to isolate each of the 3 potential TFBSs for LEF-1, as well as
the GAPDH promoter sequence used as a positive control, were
performed with specific primers listed in Table 1 and amplicons
were loaded on a ethidium bromide stained-1% agarose gel.
Determination of serum concentrations of tryptophan
and kynurenine
Trp and kynurenine (Kyn) concentrations in serum samples
from 47 male (mean age, 29.364.5 years) and 47 female (mean
age, 29.464.2 years) healthy subjects of the Haguenau cohort, that
comprise three groups of 31, 31 and 32 subjects with a *V1/*V1,
*V1/*V2 and *V2/*V2 genotype, respectively, were determined
by HPLC/MS-MS using a method described by Schefold et al.
[55], with slight modifications. One hundred mL of serum was
analysed after addition of 50 mL methanol containing methyl-
clonazepam (Sigma-Aldrich, Saint-Quentin Fallavier, France) at
1.25 mg/L as an internal standard (IS); and 50 mL acetonitrile.
The samples were mixed and then centrifuged (11200 g, 6 min).
One hundred mL supernatant was added to 500 mL deionised
water and centrifuged at 11200 g for 3 min. 15 mL were injected
into an UPLC/MS-MS system (Acquity TQ Detector, Waters,
Milford, MA) equipped with an electrospray ion source and a HSS
C18 column (1.8 mm – 2.1 X 150 mm, Waters). A positive ion
mode was used in order to detect ions, using multiple reaction
monitoring. Nitrogen was the collision gas. Flow solvent was a
gradient of acetonitrile and water containing formic acid (0.01%),
for a total run time of 5 min per sample. Quantitative precursor
ions and qualitative product ions selected for measurements of
Trp, Kyn and IS were 205.1–146.0, 209.0-94.1 and 330.1–255.1,
respectively. Calibration curves for quantification were established
with spiked samples of human albumin and correlated with the
concentration of IS. Data were analysed using Chromalynx
Software (Waters). The Kyn/Trp (mmol/mmol) ratio, an indicator
of IDO activity, was calculated by relating concentration of Kyn
(mM) to Trp (mM).
Statistical analysis
Observed genotype frequencies of the VNTR polymorphism
were examined for deviation from the Hardy-Weinberg equilib-
rium by x
2 testing. The luciferase assay data were tested using a
non-parametric Mann-Whitney test (two-tailed). The above
statistical calculations were run with the SPSS software version
15.0 (SPSS Inc., Chicago, IL). Serum Trp, serum Kyn and Kyn/
Trp ratio were each compared with genotype frequencies in all
subjects, as well as in males and females separately, using a non-
parametric Mann-Whitney test (two-tailed) with use of GraphPad
Prism version 5.02 for Windows. Findings were considered
statistically significant at p value,0.05.
Supporting Information
Table S1 Mean (6 S.E.M) luciferase activity values
observed with pGL4-basic, pGL4-V1, pGL4-V2 and
pGL4-V1mut constructs in HeLa cells.
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